Mouse TGF-beta  RIII Antibody

R&D Systems, part of Bio-Techne | Catalog # AF5034

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AF5034
AF5034-SP
Print Quote
Bulk Order
Conjugate
Catalog #
Biotin
BAF5034
View Product
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Mouse

Cited:

Mouse

Applications

Validated:

Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

View all TGF-beta RIII Antibodies »

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse TGF-beta  RIII
Gly23-Thr785
Accession # NP_035708

Specificity

Detects mouse TGF-beta RIII in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross‑reactivity with recombinant human TGF‑ beta sRII and recombinant mouse TGF‑ beta RII is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Mouse TGF-beta  RIII Antibody

Detection of Mouse TGF-beta RIII by Western Blot

Detection of Mouse TGF-beta RIII by Western Blot

MicroRNA (miRNA) 466a-3p transfection inhibits regulatory T cell (Treg) polarization. Purified naïve CD4+ T cells were cultured under Treg-polarizing conditions along with the indicated mimic, control, or inhibitor conditions. Cells were harvested 48 h after addition of cytokines and miRNA mimics, inhibitors, or controls and subject to flow cytometry, immunoblot and quantitative real-time-PCR. The success of Treg polarization is examined as (A) representative dot plots gated on CD25HI cells and quantified in (B,C). Representative immunoblots of indicated proteins are presented in (D,F), along with associated densitometric measurements of transforming growth factor-beta 2 (TGF-beta 2) and TGF-beta R3 (E), and quantification of activated Smad 2, 3, and 4 (G). CD4+ cells were purified from naïve mouse lymph nodes and stimulated ex vivo with CD3 (3 µg/mL) and CD28 (3 µg/mL) for 48 h and administered Locked Nucleic Acid or controls at the time of seeding. Quantification of flow cytometry data from LAP-expressing FoxP3 positive Treg cells. (H) Purified naïve CD4+ T cells were cultured with either TGF-beta 1 (5 ng/mL) or TGF-beta 2 (5 ng/mL), along with CD3 (3 µg/mL), CD28 (3 µg/mL), and IL-2 (5 ng/mL) for 5 days. (I) representative dot plots of FoxP3, CD4-positive Tregs gated on CD25HI, (J), and their associated CD278 (ICOS) expression. Data are presented as mean ± SEM of three independent transfection experiments. *P < 0.05, **P < 0.005, ****P < 0.0001 by ANOVA with Tukey’s multiple comparison test. Image collected and cropped by CiteAb from the following publication (https://journal.frontiersin.org/article/10.3389/fimmu.2018.00688/full), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Mouse TGF-beta  RIII Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse TGF-beta  RIII (Catalog # 5034-R3)

Reviewed Applications

Read 1 review rated 4 using AF5034 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TGF-beta RIII

Transforming growth factor beta receptor III (TGF-beta RIII; also betaglycan) is a ubiquitously expressed, 280 kDa type I transmembrane proteoglycan member of the TGF-beta superfamily of proteins (1). Mouse TGF-beta RIII is synthesized as an 850 amino acid (aa) precursor that consists of a 22 aa signal sequence, a 763 extracellular domain (ECD), a 23 aa transmembrane region, and a 42 aa cytoplasmic tail. The large ECD contains heparan sulfate and chondroitin sulfate glycosaminoglycans, five potential N-linked glycosylation sites, and a zona pellucida-like domain from residues 454‑731 (1, 2). The short cytoplasmic domain is rich in serine and threonine, but has no discernible signaling structure typical of receptor kinases (2). Proteolysis at one of two potential juxtamembrane cleavage sites (Lys743Lys and Leu750AlaValVal) allows cells to release TGF-beta RIII in a soluble form (1, 2). Mouse TGF-beta RIII shares 94%, 82%, 80%, and 67% aa sequence identity with rat, human, porcine, and chicken TGF-beta RIII, respectively (2). In all of these species, TGF beta RIII contains 17 cysteines that are 100% conserved (2). TGF-beta RIII binds with high affinity to TGF-beta 1, TGF-beta 2, and TGF-beta 3 isoforms (1). TGF-beta RIII functions by binding, and then "presenting" ligand to TGF-beta type II receptors (1, 3). It also functions to limit ligand availability to the receptor via proteolysis which releases the soluble form of TGF beta RIII along with any bound factors, making them inaccessible to cell-surface receptors (1, 3). TGF-beta RIII can therefore enhance or inhibit cell signaling. TGF-beta RIII has been shown to play an essential role in the formation of the atrioventricular cushion and coronary vessels during development of the heart (4‑6). TGF beta RIII also plays a role in many cancers. Increased expression of TGF beta RIII is found in higher grade lymphomas, and reduced expression of TGF beta RIII is found with advanced stage neuroblastomas and ovarian carcinomas (4, 7‑9). Low TGF-beta RIII expression also correlates with higher grade among a cohort of breast cancers (4, 10). Additionally, overexpression of TGF-beta RIII in MDA-231 human breast cancer cells and DU145 prostate cancer cells results in decreased tumor invasion in vitro and in vivo (4, 11, 12).

References

  1. Kolodziejczyk, S.M. and B.K. Hall (1996) Biochem. Cell Biol. 74:299.
  2. Ponce-Castaneda, M.V. et al. (1998) Biochim. Biophys. Acta 1384:189.
  3. Lopez-Casillas, F. et al. (1993) Cell 73:1435.
  4. Criswell, T.L. and C.L. Arteaga (2007) J. Biol. Chem. 282:32491.
  5. Brown, C.B. et al. (1999) Science 283:2080.
  6. Compton, L.A. et al. (2007) Circ. Res. 101:784.
  7. Woszczyk, D. et al. (2004) Med. Sci. Monit. 10:CRIII3.
  8. Bristow, R.E. et al. (1999) Cancer 85:658.
  9. Iolascon, A. et al. (2000) Br. J. Cancer 82:1171.
  10. Dong, M. et al. (2007) J. Clin. Invest. 117:206.
  11. Turley, R.S. et al. (2007) Cancer Res. 67:1090.
  12. Sun, L. and  C. Chen (1997) J. Biol. Chem. 272:25367.

Long Name

Transforming Growth Factor beta Receptor III

Alternate Names

Betaglycan, BGCAN, TBRIII, TGF-bRIII, TGFbetaRIII, TGFBR3

Entrez Gene IDs

7049 (Human); 21814 (Mouse); 29610 (Rat)

Gene Symbol

TGFBR3

UniProt

NP_035708

Additional TGF-beta RIII Products

Product Documents for Mouse TGF-beta  RIII Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Mouse TGF-beta  RIII Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.